← Back

Research · Supplements

Digestive enzymes

Prescription pancreatic enzymes raised fat and protein absorption in pancreatic insufficiency in two meta-analyses. For over-the-counter enzymes, small trials found less gas with alpha-galactosidase and fewer lactose symptoms with lactase. A 2010 review found the lactose evidence insufficient. High doses of pancreatic enzymes in children with cystic fibrosis were linked to colon strictures.

Add to Bio HackChecked 2026-11-09
Status
Enzyme blends, lactase and alpha-galactosidase are sold over the counter as dietary supplements in the US. Pancreatic enzyme products for pancreatic insufficiency are prescription drugs. FDA required them to hold an approved application by April 28, 2010.
Also called
enzyme blends, lactase, Lactaid, alpha-galactosidase, Beano, amylase, protease, lipase, bromelain, papain, pancreatin, pancrelipase, pancreatic enzyme replacement therapy, PERT, Creon, Zenpep
Taken for
digestion, bloating, gas, indigestion, lactose intolerance, beans, protein absorption, pancreatic insufficiency, autism gut symptoms

Strong several reviews agree · Moderate one review or consistent trials · Limited one or a few small studies · Untested no study in people, listed with what it rests on

What people take it for, and what was found

Shown to help4

Strong

Fat and protein absorption in pancreatic insufficiency (prescription enzymes)

Shown to raise fat absorption to about 83% from 67% on placebo in people with pancreatic insufficiency, using prescription enzymes.

The numbers and sources
Effect
Across 17 studies (511 patients), pancreatic enzyme replacement raised the coefficient of fat absorption to 83.2% against 67.4% on placebo (p 0.0001, I² 86%). It also raised nitrogen absorption and reduced stool fat, stool weight and abdominal pain, without significant adverse events [1]. A 2026 meta-analysis of 14 placebo-controlled RCTs (684 patients) found higher fat absorption (SMD 1.57, 95% CI 1.20 to 1.94) and protein absorption (SMD 1.52, 95% CI 0.97 to 2.06). Fat absorption rose in both cystic fibrosis (SMD 1.87) and chronic pancreatitis (SMD 1.08) [2].
Population
Adults with exocrine pancreatic insufficiency from chronic pancreatitis [1]; patients with exocrine pancreatic insufficiency from cystic fibrosis, chronic pancreatitis and other causes [2].
Sources
[1], [2]
Caveats
Heterogeneity was high in [1]. These are prescription products, not over-the-counter blends. The 2017 review was funded by the UK National Institute for Health Research [1]. The 2026 review reports standardized effect sizes, not percentage points [2].
Limited

Gas and bloating after beans (alpha-galactosidase)

Small trials found alpha-galactosidase reduced gas and bloating after beans in adults and in children with recurrent gas symptoms.

The numbers and sources
Effect
In 8 healthy volunteers eating 420 g of beans, 1,200 GalU of alpha-galactosidase reduced breath hydrogen and flatulence severity. Both 300 and 1,200 GalU lowered total symptom scores compared with placebo [5]. In 52 children aged 4 to 17 with recurrent gas symptoms, 2 weeks of alpha-galactosidase reduced global distress (p 0.02), days with moderate to severe bloating (p 0.03) and the share with flatulence (p 0.02). Abdominal spasms and distension did not differ [6].
Population
8 adults, single test meal [5]. 52 children [6].
Sources
[5], [6]
Caveats
Both trials were small and short.
Limited

Functional dyspepsia (enzyme blend)

One trial found a fungal multi-enzyme blend improved dyspepsia quality of life and pain scores over 2 months in 120 adults.

The numbers and sources
Effect
In 120 adults with functional dyspepsia, 2 capsules a day of a fungal multi-enzyme blend (200 mg per capsule) for 2 months improved dyspepsia quality of life, pain and sleep scores compared with placebo, with no side effects reported [7].
Population
63 men and 57 women aged 18 to 59, one center in Italy [7].
Sources
[7]
Caveats
A single trial. The abstract does not give effect sizes [7].
Limited

Protein absorption (protease with protein)

One trial found a protease blend raised the rise in blood essential amino acids by 14% after whey protein in 24 young adults. It was industry funded.

The numbers and sources
Effect
In 24 healthy young adults, 25 g of whey protein taken with a blend of 3 microbial proteases gave a 14% greater 60-minute rise in plasma essential amino acids and 15% in branched-chain amino acids than whey with placebo. Total amino acids and leucine did not differ. Ghrelin was 12% lower and fullness higher, while energy intake at the next meal did not differ [9].
Population
12 men and 12 women, mean age 25, single-dose crossover [9].
Sources
[9]
Caveats
One acute trial measuring blood amino acids, not muscle or body composition. It was funded by BIO-CAT, Inc., which supplied and distributes the product, and two authors were employees of BIO-CAT or of Iovate Health Sciences, which has sold a protein made with it [9].

Mixed results1

Limited

Lactose intolerance symptoms (lactase)

Limited evidence: a review found insufficient evidence that lactase-treated milk reduces symptoms, while one sponsored trial found lactase tablets lowered symptom scores.

The numbers and sources
Effect
A systematic review of 36 randomized studies found insufficient evidence that lactose-reduced milk, including lactase-treated milk, reduced symptoms. Most adults with presumed lactose intolerance tolerated 12 to 15 g of lactose, about a cup of milk [3]. In 47 adults with breath-test-confirmed lactose intolerance, chewable lactase tablets reduced symptom scores compared with placebo in a crossover trial, and cumulative breath hydrogen over 180 minutes was 55% lower [4].
Population
Adults with lactose intolerance or malabsorption [3]. 47 adults in India [4].
Sources
[3], [4]
Caveats
Variation in trial design prevented pooling in [3]. The sponsor of [4] supplied the tablets and placebo and paid for the breath tests.

Not shown to help1

LimitedStudied in children

Autism symptoms

One trial found digestive enzymes did not improve behavior, gut symptoms or sleep over 6 months in 43 children with autism.

The numbers and sources
Effect
In 43 children aged 3 to 8, a digestive enzyme supplement over 6 months did not improve behavior, gastrointestinal symptoms, sleep, engagement or language scores compared with placebo. Food variety scores improved slightly [8].
Population
Children with autism spectrum disorder, crossover design [8].
Sources
[8]
Caveats
One trial.

Doses studied

Alpha-galactosidase was tested at 300 and 1,200 GalU with a bean meal [5], and by body weight in children [6]. The dyspepsia trial used 400 mg a day of an enzyme blend [7]. Prescription pancreatic enzymes are dosed in lipase units. A systematic review of 25 observational studies (3,818 patients) found average real-world doses below the 40,000 to 50,000 lipase units per meal in European guidelines in 40% of studies. Diarrhea eased in nearly all lower-dose studies, but none of them showed better nutritional status. Guideline doses eased diarrhea in most studies and improved or maintained nutritional status [10]. In the cystic fibrosis study, children with colon strictures had taken a mean of 50,046 units per kg a day, against 18,985 in controls [11].

Risks

Reported risks3

ModerateStudied in children

Colon strictures with high-dose pancreatic enzymes

Linked to fibrosing colonopathy in children with cystic fibrosis on high-dose pancreatic enzymes, with risk rising steeply above 24,000 lipase units per kg a day.

The numbers and sources
Effect
In a US case-control study, 29 children with cystic fibrosis who needed colon surgery for fibrosing colonopathy were compared with 105 controls. Compared with 0 to 24,000 lipase units per kg a day, the relative risk was 10.9 at 24,001 to 50,000 units (95% CI 1.6 to 71.8) and 199.5 above 50,000 units (95% CI 9.9 to 4,026) [11]. FDA's review states that the condition is rare, mostly reported in young children with cystic fibrosis, and its cause is uncertain [12].
Population
Children with cystic fibrosis, mean age 5 [11].
Sources
[11], [12]
Caveats
Case-control data. Product strength, coating and maker were not associated with risk [11].
Limited

Product quality before FDA approval

FDA states pancreatic enzyme products were sold for decades without review, with potency varying across and within products, and that they are not interchangeable.

The numbers and sources
Effect
FDA states that pancreatic enzyme products were sold for decades without FDA review, that formulation and manufacturing differences caused potency to vary across products and within a single product, and that the products are not interchangeable. This led to its 2004 notice requiring approval [12].
Population
Pancreatic enzyme products in the US [12].
Sources
[12]
Caveats
A regulatory review of prescription products. No potency analysis of over-the-counter enzyme blends was sourced for this page.
Limited

Other label warnings for pancreatic enzymes

FDA's review lists mouth irritation, raised uric acid, hypersensitivity reactions and a theoretical risk of viral transmission from pig pancreas, with none documented.

The numbers and sources
Effect
FDA's review lists irritation of the mouth when the coating is broken, raised uric acid in blood and urine, hypersensitivity reactions, and a theoretical risk of viral transmission because the products come from pig pancreas. FDA notes no viral illness from these products has been documented [12].
Population
Users of porcine pancreatic enzyme products [12].
Sources
[12]
Caveats
Label warnings drawn from the literature, without rates.

Claims tested and not found

  1. That digestive enzymes improve autism symptoms. Behavior, gut symptoms, sleep and language did not differ from placebo over 6 months [8].
  2. That lactose-reduced or lactase-treated milk reduces lactose intolerance symptoms. A systematic review found the evidence insufficient [3].

Sources

  1. de la Iglesia-García D, Huang W, Szatmary P, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut. 2017. https://doi.org/10.1136/gutjnl-2016-312529
  2. Yang X, Yang L, Zhang W, et al. Efficacy of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology. 2026. https://doi.org/10.1097/MEG.0000000000003225
  3. Shaukat A, Levitt MD, Taylor BC, et al. Systematic Review: Effective Management Strategies for Lactose Intolerance. Annals of Internal Medicine. 2010. https://doi.org/10.7326/0003-4819-152-12-201006150-00241
  4. Baijal R, Tandon RK. Effect of lactase on symptoms and hydrogen breath levels in lactose intolerance: A crossover placebo-controlled study. JGH Open. 2021. https://doi.org/10.1002/jgh3.12463
  5. Di Stefano M, Miceli E, Gotti S, et al. The Effect of Oral α-Galactosidase on Intestinal Gas Production and Gas-Related Symptoms. Digestive Diseases and Sciences. 2007. https://doi.org/10.1007/s10620-006-9296-9
  6. Di Nardo G, Oliva S, Ferrari F, et al. Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. BMC Gastroenterology. 2013. https://doi.org/10.1186/1471-230x-13-142
  7. Ullah H, Di Minno A, Piccinocchi R, et al. Efficacy of digestive enzyme supplementation in functional dyspepsia: A monocentric, randomized, double-blind, placebo-controlled, clinical trial. Biomedicine & Pharmacotherapy. 2023. https://doi.org/10.1016/j.biopha.2023.115858
  8. Munasinghe SA, Oliff C, Finn J, et al. Digestive Enzyme Supplementation for Autism Spectrum Disorders: A Double-Blind Randomized Controlled Trial. Journal of Autism and Developmental Disorders. 2010. https://doi.org/10.1007/s10803-010-0974-2
  9. Huang Y, Bell ZW, Alhamwi A, et al. Acute Effects of Oral Microbial Protease Co-ingestion with Whey Protein on Postprandial Plasma Amino Acid Concentrations, Appetite, and Satiety in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial. Journal of Nutrition. 2025. https://doi.org/10.1016/j.tjnut.2025.07.006
  10. Kadaj-Lipka R, Monica M, Stożek-Tutro A, et al. Pancreatic Enzyme Replacement Therapy in Pancreatic Exocrine Insufficiency-Real-World's Dosing and Effectiveness: A Systematic Review. Digestive Diseases and Sciences. 2025. https://doi.org/10.1007/s10620-025-09011-0
  11. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-Dose Pancreatic-Enzyme Supplements and Fibrosing Colonopathy in Children with Cystic Fibrosis. New England Journal of Medicine. 1997. https://doi.org/10.1056/NEJM199705013361803
  12. U.S. Food and Drug Administration. Division Director Summary Review, NDA 22-210 (Zenpep, pancrelipase). Center for Drug Evaluation and Research. 2009. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022210s000sumr.pdf

Everything in the library